Close Icon We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Products:

Pharma Consulting

Conferences 2020

Awards

Upcoming Webinars

Webinar recordings

Close Icon

Global Search Configuration

Search Site Products & Services
Close Icon

Search by Keyword

Focus
Needs

Pharmaceutical intelligence for consultancies

Focus on your clients and expand your business opportunities. We’ll help you build a complete picture of the rapidly changing pharmaceutical market with our insight and expertise.

Your trusted pharma partner

With the pharma and healthcare sector facing increasing challenges, your clients rely more than ever on independent intelligence. Pharma Intelligence will help you make smart decisions and stay ahead of a fast changing market.

What we offer

As the trusted partner of the top 50 pharmaceutical companies and 10 contract research organizations, our wide range of solutions cover early phase, clinical R&D, portfolio and strategy, regulatory and commercial planning and analysis.

We cover the life sciences business from drug and device discovery and development to regulatory approval, and drug reimbursement to lifecycle management. And we give you access to past, current and future trends and analysis.

How it helps

Whether you’re working on your next business pitch, engaging on a project for an existing client or working on due diligence for a proposed merger or acquisition; our pharmaceutical intelligence helps you meet the demands of dynamic markets and changing customer needs, with:

Expert analysis of key pharma sectors
In-depth knowledge from drug discovery to market access
Global coverage including digital health, R&D, and emerging markets
Precise analysis and data
Customized reports

Our unique strengths

Understand your clients’ world

Gain a comprehensive understanding of the global pharma market with our complete coverage.

Stay on top of the details

We’ll keep you in touch with complex regulatory and pricing and reimbursement issues.

Think ahead

Respond to market events, identify opportunities and anticipate changes by tracking drug pipelines, patent expiration and commercial activities influencing the landscape.

Deliver tailored solutions

Use our data and insight to create solutions to suit your clients’ needs.

Benefit from a dedicated service

Our services come with dedicated client service and analyst support.

View more
View Less

Relevant products

Datamonitor Healthcare: data analysis and insight

Datamonitor Healthcare's expert coverage of key diseases, companies, drugs and market trends makes it the go-to product for pharmaceutical and biotechnology companies to support the development and validation of their strategic plans and commercial decisions.

Key benefits:

Prioritize market opportunities
Identify unmet needs
Make informed decisions

Thought leadership

Key benefits:

Build brand credibility
Generate Leads
Effective reporting

Our products and audiences

Key benefits:

Tailored and targeted campaigns
Multiple channels and content formats
Right message for the right audience

View all content

Scrip

Coronavirus Update: US Adds To Antibody Push With $486m AstraZeneca Deal

After a week of monoclonal antibody therapies hitting the headlines - including a personal endorsement from President Trump - the US government bulks up its potential supplies. AZ's long-acting monoclonal antibody product enters large-scale trials for both a treatment and prophylaxis of COVID-19.

Topic Coronavirus

View article
Scrip

J&J Says It's Wait And See On COVID-19 Vaccine Delay Outlines Rosier Outlook for 2021

It will be several days at least before more information is available about the unexpected illness in J&J's Phase III COVID-19 vaccine trial, the firm said during its third quarter financial call.

Topic Coronavirus Vaccines Clinical Trials

View article
HBW Insight, Generics Bulletin, Medtech Insight, Datamonitor...

Pharma Intelligence Launches Alexa Skill

Keep up with topics you care about in Pharma and Medtech with the new Alexa Skill from Informa Pharma Intelligence. Access daily news briefings to stay up to date with the latest news, right from your Alexa smartphone app!

Topic Artificial Intelligence Consumer Innovation

View article
Scrip, Datamonitor Healthcare

Top 10 Best-Selling Drugs of 2019

In 2019, the 10 most lucrative medicines generated combined global sales of $92.5B. Scrip provides insight into these top sellers and the companies behind them, as well US dynamics, global sales forecasts and lifecycle data, with complementary market analysis from Datamonitor Healthcare on diseases targeted, indications, and more.

Topic Drug Review Diseases

Single report
Scrip

Quick Listen: Scrip's Five Must-Know Things

Join us for an audio roundup of major events in the international biopharma industry over the past week, as reported by Scrip's global team

Topic Coronavirus Clinical Trials

Full podcast
Scrip

Vir/GSK Move Lead Coronavirus Antibody Into Phase III

Results from a Phase II/III study for VIR-7831 in the prevention of hospitalization due to COVID-19 are expected in late 2020 and early 2021.

Topic Coronavirus Research & Development

View article
Pink Sheet, Scrip

Executive Privilege: How Giving Trump Special Access To Experimental COVID Treatment Could Backfire

Trump receives Regeneron’s experimental antibody under FDA’s expanded access program, Gilead’s remdesivir and dexamethasone. The president’s treatment choices could influence clinical trials of all COVID-19 medicines and even trial recruitment for other diseases, experts said.

Topic Coronavirus US Election 2020 Clinical Trials

View article
Pink Sheet

US Election 2020: Trump's Sway Over Courts Expected To Linger

Textualist judges appointed by President Trump during his term may block a potential President Biden’s attempts to shift the government’s legal policies.

Topic US Election 2020 Policy & Regulation

View article
Pink Sheet

VP Debate: Pence Tries Vaccine Hesitancy Jujutsu On Harris

‘Senator, please stop undermining confidence in a vaccine,’ Pence says when confronted with the accusation that the administration is politicizing the COVID vaccine development effort.

Topic Coronavirus Vaccines US Election 2020

View article
Pink Sheet

EU Pharma Strategy To Balance Innovation Incentives and Competition

Delegates at this week’s TOPRA conference heard the European Commission’s “holistic” vision of what it would like to achieve through its pharmaceutical strategy, including incentives for innovation, security of the supply chain, product shortages, real world evidence and big data, and the availability and affordability of medicines.

Topic EU Artificial Intelligence Regulation

View article
Pink Sheet

US FDA 'Flexible' With Vaccine Safety Data Requirements, CBER's Peter Marks Says

The median of two months of follow-up is not absolute, but agency flexibility is limited.

Topic Coronavirus Vaccines

View article
Biomedtracker, Datamonitor Healthcare

Key Potential Drug Launches in 2021

Valuable insight and expert analyst commentary 2021’s expected drug launches, their indications, commercial potential, regulatory catalysts and more.

View article
Pink Sheet

'Like Water': Pharma Avoids Much Scrutiny In Messy Presidential Debate

Trump and Biden trade barbs in debate that included a suggestion by the president that coronavirus vaccine development delays are political and saw Biden questioned on whether he was contributing to vaccine hesitancy.

Topic US Election 2020 Drug Pricing Policy & Regulation

View article
Pink Sheet

'No Turning Back' On Regulatory Changes at UK MHRA

The UK medicines regulator has a “unique opportunity” to evaluate the systems it operates and to “do things differently", according to its long-term interim head, June Raine.

Topic Policy & Regulation Brexit

View article
Pink Sheet

Hahn Says COVID Vaccine Review Could Take Months As Trump Floats Rejecting New EUA Guidance

Commissioner’s comments were yet another sign that US FDA won’t clear a vaccine ahead of the election, but hours later the president suggests the White House may decline to clear the agency’s new guidance on emergency use authorization standards for COVID-19 vaccines, raising new concerns about political interference in any decisions.

Topic Coronavirus Vaccines FDA

View article